Plasma progesterone levels after using high dose suppositories. A preliminary report

1982 ◽  
Vol 4 (5) ◽  
pp. 135-136 ◽  
Author(s):  
Y. G. Van Der Meer ◽  
A. C. Van Loenen ◽  
E. W. Loendersloot ◽  
L. J. B. Jaszmann
2021 ◽  
pp. 105381
Author(s):  
Georg S. Kranz ◽  
Marie Spies ◽  
Chrysoula Vraka ◽  
Ulrike Kaufmann ◽  
Eva-Maria Klebermass ◽  
...  

2021 ◽  
Author(s):  
Fang Wang ◽  
Shijie Li ◽  
Lingshuai Meng ◽  
Ye Kuang ◽  
Zhonghua Liu ◽  
...  

Implantation timing is key for a successful pregnancy. Short delay in embryo implantation caused by targeted gene ablation produced a cascading problem in the later stages of the pregnancy. Although several delayed implantation models have been established in wild mice, almost none of them is suitable for investigating the delay on the late events of pregnancy. Here, we report a new delayed implantation model established by the intraperitoneally administration of letrozole at 5 mg/kg body weight on the day 3 of pregnancy. In these mice, initiation of implantation was induced at will by the injection of estradiol (E2). When the estradiol (3 ng) was injected on day 4 of pregnancy (i.e., without delay), the embryo implantation restarted, and the pregnancy continued normally. However, high dose of estrogen (25 ng) caused compromised implantation. We also found that only 67% of the female mice could be pregnant normally and finally gave birth when the injection of estradiol (3 ng) was on day 5 of pregnancy (i.e., one day delay). Most of the failed pregnancies had impaired decidualization, decreased plasma progesterone levels and compromised angiogenesis. Progesterone supplementation could rescue decidualization failure in the mice. Collectively, we established a new model of delayed implantation by letrozole, which can be easily used to study the effect and mechanisms of delay of embryo implantation on the progression of late pregnancy events.


Author(s):  
Cristiano Van Zeller ◽  
Asad Anwar ◽  
Nordita Ramos-Bascon ◽  
Natalie Barnes ◽  
Brendan Madden

COVID-19 ARDS has a high mortality and few therapeutic options. We present a preliminary report on our experience using high-dose pulsed methylprednisolone in COVID-19 ARDS and three-month outcomes. We performed a retrospective analysis of all patients treated with high-dose methylprednisolone for COVID-19 ARDS and three-month lung function, 6MWT, and CT findings. 15 patients were treated of which 10 survived to discharge. Reduced DLCO was the commonest abnormality in lung function tests and had the lowest mean value. Parenchymal bands were the commonest CT finding and 50% of patients had fibrosis at three-months. Mean 6MWD was 65.4% predicted and was abnormal in 62.5% of patients. In this cohort of patients with COVID-19 ARDS treated with high-dose methylprednisolone pulses, CT, lung function, and 6MWT abnormalities were unsurprisingly common at three months, although all 10 patients treated early in their disease course survived, a possible therapeutic effect. Further randomised controlled trials are needed to assess the benefits of this treatment.


1991 ◽  
Vol 41 (3) ◽  
pp. 212-216 ◽  
Author(s):  
Pierluigi Benedetti Panici ◽  
Stefano Greggi ◽  
Giovanni Scambia ◽  
Guglielmo Ragusa ◽  
Gabriela Baiocchi ◽  
...  

1976 ◽  
Vol 1 (7-8) ◽  
pp. 717-727 ◽  
Author(s):  
Omar M. Salazar ◽  
Philip Rubin ◽  
Joseph V. Mcdonald ◽  
Michael L. Feldstein

Lung Cancer ◽  
1998 ◽  
Vol 21 ◽  
pp. S51
Author(s):  
J Kozielski ◽  
K Oklek ◽  
A Krzywiecki ◽  
D Ziora ◽  
A Polońska ◽  
...  

2004 ◽  
Vol 25 ◽  
pp. S193
Author(s):  
Mark D. Pass ◽  
Joshua R. Shua-Haim ◽  
Suhas Patel ◽  
Sameer Patel ◽  
Paul Lee ◽  
...  

2000 ◽  
Vol 55 ◽  
pp. 91
Author(s):  
Eashwer K. Reddy ◽  
J. Brantley Trasher ◽  
Rajendra Kurup ◽  
Alvaro Alvarez-Farinetti ◽  
Eric Kiefer

Sign in / Sign up

Export Citation Format

Share Document